![功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第1頁(yè)](http://file4.renrendoc.com/view/497937e0befd33816e74630308f7873f/497937e0befd33816e74630308f7873f1.gif)
![功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第2頁(yè)](http://file4.renrendoc.com/view/497937e0befd33816e74630308f7873f/497937e0befd33816e74630308f7873f2.gif)
![功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第3頁(yè)](http://file4.renrendoc.com/view/497937e0befd33816e74630308f7873f/497937e0befd33816e74630308f7873f3.gif)
![功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第4頁(yè)](http://file4.renrendoc.com/view/497937e0befd33816e74630308f7873f/497937e0befd33816e74630308f7873f4.gif)
![功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用_第5頁(yè)](http://file4.renrendoc.com/view/497937e0befd33816e74630308f7873f/497937e0befd33816e74630308f7873f5.gif)
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
功能影像學(xué)技術(shù)在頭頸部腫瘤放療計(jì)劃制定療效評(píng)估和個(gè)體化治療中應(yīng)用Role
of
routine
and
functional
Imaging(FI)Screening
and
diagnosis
of
neoplasmsPrecisestaging
of
malignancyResponse
assessment
of
cancer
treatmentMonitor
recurrencesBenefit
of
FIMajor
modalities
of
FI:positronemissiontomography(PET)combinedwithCTormagneticresonance(MR)imagingfMRI:
DWI,
DCE-MRI,
BOLD,
spectroscopy
etc.Emerging
techniques:
PET-MRI,
DKI,
IVIM,
APT,
CEST
etc.Offercomplementaryinformationincluding
metabolism
of
FDG,proliferation,hypoxia,andcellmembranesynthesisby
PEThypoxia
and
permeability
by
DCE
MRI
and
IVIM,cellproliferationandapoptosis
by
DWI,
IVIM
and
DKI,andepidermalgrowthfactorreceptorstatus.About
this
articlePart
I:
Discussesthepracticalaspectsofintegratingfunctionalimagingintohead-and-neckradiationtherapyplanning.Part
II:
Reviewsthepotentialofmolecularimagingbiomarkersforresponseassessmentandtherapyadaptation.Authors
concluded
that
FI
allowedmoreindividualizedtreatmentplanninginpatientswithheadandneckSCCsintheemergingeraofpersonalizedmedicine.Part
I
RoleofFunctionalImaginginRadiationTherapyPlanningTherewasa20%decreaseinOS
amongpatientswhounderwentradiationtherapywithaprotocolthatdidnotcomplywithestablishedinstitutionalstandards.Reasons:
Inaccuraciesintumortargetdelineation
Inter-observervariabilityin
clinical
practice
based
on
CT
fortargetdelineationFunctionalMRIandPETtechniquesprovidedifferentandpotentiallycomplementaryinformationaboutthetumorextentandbiologicactivity.PET-basedTumorTargetContouringTumoruptakeofPETradioactivetracerscanprovideexcellentcontrastresolutionbetweenneoplasticandnormaltissues.There
are
two
DOSE
CONTOURING
methods:
visualinterpretationandautomateddelineationmethods.Example
of
automateddelineationFigure2.SCCarisingfromtheepiglottis(T2N2bM0)ina67-year-oldman.AxialfusedFDGPET/CTimageshowstumorcontoursautomaticallygeneratedwithdiagnosticsoftware.Automated
delineation
is
believe
to
be
more
objective
than
visual
delineation.
Because,
analterationoftheSUVscalecanchangetheapparenttumorvolumeandleadtoincreasedinter-observervariability.Status
of
PET-contouring
at
presentAtpresent,thereisnoconsensusregardingtheoptimalcontouringmethod.ThemostpracticalapproachtodefiningthetumortargetistorelyonexpertvisualinterpretationsbynuclearmedicinephysiciansandradiologistsAnd
rely
onknowledgeofthelikelypatternsofdiseaseinfiltrationwithinstrictSUVscalelimits.However,limitedspatialresolutionandpartialvolumeeffectsblurtheedgesofFDG-avidtumorsatPET.PET-basedRadiationTherapyPlanningtheFDGPET–definedgrosstumorvolume(GTV)wasfoundtobesmallerandmoreaccuratethantheCT-orMRimaging–definedGTVandclosertothetumorvolumeatpathologicanalysis.however,nosingleimagingmodalityallowedperfectlyaccuratethree-dimensionalestimationofthetumorvolume.Allmodalitiesfailedtodetectabout10%ofthetumorvolume,mainlybecauseofsuperficialtumorextension.PETwasfoundtoallowtheidentificationofpotentialdiseaseextensionbeyondtheCT-definedGTVin29%–64%ofcases.PET-basedRadiationTherapyPlanningDuprezetal(24)demonstratedthefeasibilityofapplyingdoseescalationtoanFDGPET–avidGTVwithdosepaintingbynumbersinsteadofwithGTVcontouring.TheuseofmultimodalityimagingraisesthequestionofwhethertheGTVshouldbedefinedonthebasisofimagingwithonlyoneorwithseveralmodalities?
Thelackofconcordancefoundbetweenvariousimagingmodalitiessuggeststhatthesafestapproachwhendefiningatargetistouseallimagingmodalitiesalongwithphysicalexamination.
Anatomicandfunctionalimagingmodalitiescould
providedifferentbutcomplementaryinformationduringcontouring
and
planning
for
cancer
RT
treatment.Contourlinesarecolorcodedtoshowtheimagingmodalityonwhichtheyarebased(green=CT,blue=MRimaging,orange=PET).AdaptiveRadiationTherapyPlanningThereisconsiderableinterestinpersonalizingtreatmentinanattempttooptimizethetherapeuticratioforindividualpatients.Oneavenueforachievingthisistoalterthedeliveryofradiationtherapyonthebasisofchangesinthetumorand/ornormalorgansduringacourseoftreatment.Mainly
current
radiationtherapyisplannedatasinglepretreatmenttime-pointtodelineatethetargetvolumeandanyorgansatrisk,withnoaccounttakenofanatomicchangesduringthecourseoffractionatedradiationtherapy.AdaptiveRadiationTherapyPlanningGeetsetal
showedreductionsof51%intheclinicaltargetvolumeand48%intheplanningtargetvolumeafterapartialcourse(45-Gydose)ofradiationtherapy.InasubsequentstudyofpatientsreceivingCRT
therapyforlaryngopharyngealcancer,PET-basedandCT-basedprimarytumorGTVswerefoundtodecreaseatameanrateof3.2%and3.9%pertreatmentday,respectivelywhilenodalGTVsdecreasedatarateof2.2%pertreatmentday.Inaddition,positionalshiftswerenotedintheGTV.AdaptiveRadiationTherapyPlanningIt
providesanopportunitytoimprovethetherapeuticratiobyminimizingtheoveralldosetoorgansatriskandescalatingthedosetoareasoftumortissue.18F-fluorothymidine(FLT)PET/CTisanoninvasivemethodformonitoringproliferationduringtreatment.Troostetalshowedthatdecreasesintumor-relatedFLTuptakeoccurredearlyaftertheadministrationofthefifthradiationdosefraction.Bycontrast,changesintheCT-definedGTVweredetectableonlyafter4weeksofradiationtherapy.Thesedatademonstratedthefeasibilityofescalatingtheradiationdoseadministeredtotumorsub-volumeswithhighproliferativeactivityinthe2ndweekoftreatment.Figure6.Adaptivetherapyplanningina68-year-oldmanwithasupraglotticSCC(T2N2bM0)treatedwithchemoradiationtherapy.(a)AxialfusedPET/CTimageobtainedbeforethestartoftherapyshowsmarkedmetabolicactivity(SUVmax,22.2)inthetumor(arrowhead).(b)AxialfusedPET/CTimageobtainedafter11fractionsofradiationtherapyshowsareductionintumorsizeandmetabolicactivity(SUVmax,9.7).(c)AxialfusedPET/CTimage,obtainedafter21fractionsofradiationtherapy,showscontinuedreductionintumorsizeandmetabolicactivity(SUVmax,7.9).AdaptiveRadiationTherapyPlanningOther
limited
fMRI
data
alsosuggestthatchangesondiffusion-weightedordynamiccontrast-enhancedMRimagescouldbeusedtoguideadaptivedoseescalationstrategies.a
and
b
–beforec
and
d
–after
21
fractionshowthetumor(arrow)andnode(arrowhead)withreducedsignalintensityincandincreasedsignalintensityind,findingsindicativeofresponsetotreatment.Mainly
issues
of
FI
to
guide
A-RT
planning1、thechoiceofimagingmodality.2、imagingcharacteristicsmaynotbe
reproducibleatsuccessiveimagingevaluations.3、theoptimaltimingofimagingassessmentsduring
thecourseoftreatmentisunknown.4、theoptimalmethodfordefiningtumorcontours
isunclear.PART
II
FunctionalImagingforDiseaseResponseAssessmentfunctionalimagingappearstobeapromisingadditiontoclinicalexaminationandanatomicimagingforassessingtheresponseofheadandneckSCCtumorstoradiationtherapy.Thisisparticularlytrueintheclinicalscenarioofresidualmasses,whereanatomicimagingtechniquesareinaccurate.TheuseofFDGPETisnowsupportedbyconsiderabledata.ArolealsomaybeestablishedforotherPET-andMRimaging–basedtechniques.I
selected
fMRI
as
my
favorite
lecture
today.
While
leave
PET
for
colleaguefrom
nuclear
medicine
department.FunctionalMRImagingTechniquesAdvancedMRimagingtechniquessuchasdynamiccontrast-enhancedimaging,diffusion-weightedimagingbloodoxygenationlevel–dependent(BOLD)imagingspectroscopyholdthepromiseofprovidingfunctionalinformationaboutdisease.Thesetechniquescanbeusedforplanning,monitoring,andassessingtheresultsofradiationtherapyinpatientswithheadandneckSCCs.DynamicContrast-enhancedImagingitisanoninvasivetechniquethathelpscharacterizethemicrovasculature,therebyprovidingmarkersspecifictoperfusion,permeabilityofbloodvessels,andthevolumeofextracellularspace.Abnormalmicrovesselsseenatdynamiccontrast-enhancedMRimagingthemselvesmaybeamarkerofhypoxiaTumorangiogenesisisassociatedwithchaoticvesselformationandincompetentarteriovenousshunts,whichleadtolesseffectiveperfusionandamorehypoxicenvironmentthanexistsinnormaltissues.Previous
studies
of
DCE
MRINewboldetaldemonstratedastatisticallysignificantcorrelationbetweenvariousDCE-MRI
parameters,particularlyKtrans(whichrepresentsthepermeabilityofbloodvessels)andpimonidazolestaining(anexogenousmarkerforhypoxia).TheappearanceofheadandneckSCCsatdynamiccontrast-enhancedMRimagingalsohasbeenusedtosuccessfullypredicttreatmentresponsetochemoradiationtherapyinthetumors(85).(a)AxialT1-weightedMRimageobtainedforplanningofchemoradiationtherapyina62-year-oldmanshowsaprimarySCCintheleftaspectofthetonguebase(T4N2bM0)(arrow)andanodalmetastasis(arrowhead).(b,c)Axialdynamiccontrast-enhancedMRimagesbefore
and
after
RTshowincreasedvascularpermeability(Ktrans)beforeradiationtherapyintheprimarytumor(arrowinb)andcervicalnode(arrowheadinb)decreasedpermeabilityafter11fractionateddosesofradiationtherapyinthetumor(arrowinc)andnode(arrowheadinc).Thesefindingsareindicativeoftherapeuticresponse.Diffusion-weightedImagingDiffusion-weightedMRimagingisanoninvasiveimagingtechniquethatfacilitatestissuecharacterizationonthebasisofthemolecularmotionofwatermolecules.DiffusionisquantifiedbyusingtheADC,whichisinverselycorrelatedwithcellularityandisapotentialbiomarkerforapoptosis.TheincreaseddensityofcellswithinmalignantlymphnodesreducestheirADCatdiffusion-weightedMRimaging.StudieshaveshownthatDWIcanbeusefulfordifferentiatingsmallmalignantlymphnodesfromnonmalignantonesInonestudy,asensitivityof76%wasobtainedwiththeuseofADCatdiffusion-weightedimagingfordetectingsubcentimetriclymphnodemetastases,incomparisonwithasensitivityof7%obtainedwiththeuseofmorphologicfeaturesandsizedepictedatconventionalMRimagingInanotherstudy,in33patientswithheadandneckSCCs,changeinADCwasusedasamarkeroftumorresponsejust
1weekafterchemoradiationtherapy.Dirixetal(31)evaluatedtheusefulnessofDWIforradiationtherapyplanninga
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年度企業(yè)財(cái)務(wù)風(fēng)險(xiǎn)預(yù)警系統(tǒng)合同
- 2025年一般貨物運(yùn)輸合同參考模板(4篇)
- 2025年度二零二五版股票質(zhì)押擔(dān)保糾紛解決合同模板
- 2025年度企事業(yè)單位綠化養(yǎng)護(hù)服務(wù)勞務(wù)承攬合同
- 2025年度環(huán)保設(shè)備制造就業(yè)安置合同范本
- 2025年度公路汽車貨運(yùn)車輛運(yùn)輸合同范本
- 2025年度劃撥土地房屋買賣合同違約責(zé)任及賠償細(xì)則
- 2025年度戶外景觀綠化場(chǎng)地租賃合同
- 2025年度文化旅游產(chǎn)業(yè)投資合同
- 2025年上海公寓房預(yù)定合同格式版(三篇)
- (康德一診)重慶市2025屆高三高三第一次聯(lián)合診斷檢測(cè) 英語(yǔ)試卷(含答案詳解)
- 2025年福建泉州文旅集團(tuán)招聘24人高頻重點(diǎn)提升(共500題)附帶答案詳解
- 建筑行業(yè)砂石物資運(yùn)輸方案
- 腫瘤全程管理
- 桃李面包盈利能力探析案例11000字
- GB/Z 30966.71-2024風(fēng)能發(fā)電系統(tǒng)風(fēng)力發(fā)電場(chǎng)監(jiān)控系統(tǒng)通信第71部分:配置描述語(yǔ)言
- 污泥處置合作合同模板
- 2025高考數(shù)學(xué)專項(xiàng)復(fù)習(xí):概率與統(tǒng)計(jì)的綜合應(yīng)用(十八大題型)含答案
- 2024-2030年中國(guó)紫蘇市場(chǎng)深度局勢(shì)分析及未來(lái)5發(fā)展趨勢(shì)報(bào)告
- 2024年高中一年級(jí)數(shù)學(xué)考試題及答案
- 建設(shè)工程施工合同糾紛處理課件
評(píng)論
0/150
提交評(píng)論